Listen Score
LS 34
Global Rank
TOP 5%

INFORMAZIONI SU QUESTO PODCAST 🔗

Conduttori:
Frequenza di aggiornamento:
every 110 days
Durata media dell'audio:
29 minutes
Interviste agli ospiti
Inglese
Stati Uniti
38 episodi
da 08 Ottobre 2019
episodic

ULTIMO EPISODIO 🔗

Discover how multimodal and longitudinal data are transforming drug discovery and personalized medicine. Alessandro Riccombeni, CEO of Axia Medicine, discusses health AI, interoperability, clinical trials, and the future of connected health data.

CERCA TRA GLI EPISODI PASSATI

Cerca gli episodi passati di BioRad.io.

EPISODI PRECEDENTI

Explore how AI is transforming drug discovery. Learn how generative and agentic AI, data integration, and workflow optimization can accelerate research, overcome challenges, and drive collaboration in pharmaceutical R&D.
Learn how AI can help you manage complex biological data in biopharma. Explore strategies for better software, databases, and data standardization to stay compliant, enable innovation, and build a strong foundation for AI-driven drug discovery.
Discover the future lab, an ecosystem where digital transformations shape the landscape of biopharma research, driving innovation and unlocking the potential of tomorrow's therapies.
Data silos and challenges around data fragmentation and interoperability hinder holistic insights and innovation in R&D. Employing strategy around the patient at the center of data interoperability can provide accelerated insights and innovation through a unified approach to data management.
Historically, cancer drug development has a high failure rate. Why is that, and how can we facilitate success? Listen in as we chat with the co-founder of a company that is trying to shift the paradigm using AI and machine learning.
From antibiotics to cancer drugs, fungi and other microbes have long been a rich source of medicinal compounds. In this episode, we discuss how one company sequences and mines novel fungal genomes to discover and engineer new therapeutics.
Early detection of cancer and other diseases can significantly improve patient prognosis. Join us for a practical discussion about the challenges of developing noninvasive early screening tools, from biomarker identification to clinical performance.
Precision medicine is a multifaceted approach to designing and delivering individualized patient treatments. Using multi-omic, environmental, lifestyle, and other data, researchers aim to more accurately develop treatment and prevention strategies tailored to each unique patient. The promise of pre…
The relatively high failure rate of new candidate drugs is a key issue in pharma and biopharma R&D. Listen in as we discuss how artificial intelligence, machine learning, and the ever-increasing availability of biological datasets can improve prospects.
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da Bio-Rad Laboratories, Inc., che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.